How to Prepare a CDMO Partnership: RFP, Tech Transfer, Quality Agreement and Contract Terms

The Short Answer

A CDMO partnership is prepared, not just signed. Choosing the partner is only the start; our CRO vs CDMO guide covers what a CDMO does and how to choose one. What decides whether the partnership works is what happens around the choice: the package you send before the RFP, the audit, a technology transfer planned as a project, a quality agreement that sets out who is responsible for what, and commercial terms that hold up when a batch fails or you need to leave.

The stakes are rising. Biologics CDMO revenue was estimated at between US$25 billion (Mordor Intelligence) and US$48 billion (Grand View Research) in 2025, depending on how the market is defined, growing about 7% a year. Capacity is also changing hands: Samsung Biologics agreed to buy GSK’s Rockville, Maryland site, with 60,000 liters of drug-substance capacity, for US$280 million, and launched a tender offer for the peptide CDMO PolyPeptide worth about CHF 1.46 billion. Our CDMO market analysis covers the providers and the market in depth; this guide covers the preparation.

A Realistic Timeline

Most delays come from starting too late. These are the ranges practitioners and CDMOs report; your own fit/gap analysis will narrow them.

Published ranges for small-molecule transfers vary too widely to quote with confidence. Treat any single number, including a CDMO’s own best case, as a starting point for your plan rather than the plan itself.

What to Prepare Before the RFP

CDMOs say the RFPs they can answer well describe the molecule and the process plainly and admit what is not yet known. Before you approach anyone, assemble:

• The process: expression system, upstream and downstream steps and a process map, or the synthetic route for a small molecule
• The evidence: formulation, analytical methods, specifications, stability data and batch history
• The gaps: an honest list of what is missing or unproven
• The need: whether material is for GLP or GMP use, the timeline and how fixed it is, batch numbers and scale
• The forecast: demand by development phase, with ranges rather than false precision
• The rules: budget, the contract terms you expect and how you will score proposals

For the technology transfer itself, CDMOs will want batch records, analytical methods, raw-material specifications, the cell bank package and, for biologics, qualified scale-down models. The element practitioners call the most valuable and the most often missing is the process development history: why the process looks the way it does. Documents alone rarely transfer a process; plan for your experts to work with theirs.

Running the RFP and Shortlisting

GMP status is a threshold, not a differentiator. Shortlist on:

• Experience with your modality and scale
• Inspection history with FDA and EMA, including Form 483 observations and warning letters
• In-house analytical and potency testing, rather than subcontracted methods
• Realistic capacity, with room for a repeat batch if one fails
• A named, dedicated project manager
• Financial health, insurance cover and how dependent the CDMO is on a few large clients

Two free databases are worth checking before the first visit: FDA’s Data Dashboard (inspection classifications, warning letters, recalls and import refusals) and the EU’s EudraGMDP database (GMP certificates and statements of non-compliance).

Location now affects cost as well as risk. Since September 29, 2026, Section 232 tariffs apply to covered patented pharmaceutical imports into the US, with lower negotiated rates for the EU, Japan, South Korea and Switzerland; our pharma tariffs guide explains who pays what.

Diligence and the Qualification Audit

Outsourcing manufacturing does not outsource responsibility. FDA’s guidance on quality agreements for contract manufacturing is explicit that the product owner’s quality unit approves or rejects what the contractor makes, including final release, and that a quality agreement cannot be used to hand over the duty to comply with cGMP. FDA treats a contract facility as an extension of the manufacturer’s own.

Europe says the same in different words. Chapter 7 of the EU GMP guide makes the contract giver ultimately responsible, requires it to assess the contract acceptor’s legality, suitability and competence before work starts, and requires a written contract that gives the right to audit the acceptor and its subcontractors. ICH Q10 keeps responsibility for outsourced activities with the company, and ICH Q9 names the evaluation of contract manufacturers as a use of quality risk management.

In practice the qualification audit should cover the quality system, change control, deviation and investigation handling, data integrity, the specific suite and equipment your process will use, and how the CDMO manages its own subcontractors.

Technology Transfer, Step by Step

Run the transfer as a project with a plan, owners on both sides and decision points. A typical sequence for biologics:

1. Fit/gap analysis of your process against the CDMO’s facility, equipment and procedures
2. Risk assessment of the gaps and what could go wrong at scale
3. Analytical method transfer, often the critical path
4. Verification or engineering run at the new site
5. Process characterization to confirm the operating ranges
6. Process performance qualification before commercial supply

A transfer is only finished when the regulators have approved the new site. The usual failure points are a process that was never robust in the first place, which Pfizer CentreOne calls the most influential factor, gaps in equipment, utilities and procedures between the two sites, slow analytical methods and change control started too late.

The Three Agreements

Most CDMO relationships rest on three documents, and keeping them apart avoids problems later:

• Master services agreement: the commercial terms, including scope, pricing, IP, confidentiality, liability and termination
• Quality agreement: who is responsible for each GMP activity
• Supply agreement: forecasts, orders, capacity, pricing and delivery for clinical or commercial supply

FDA recommends that the quality agreement cover the scope, definitions, dispute resolution and the manufacturing activities: each party’s quality-unit role, facilities and equipment, materials, laboratory controls, documentation and change control, plus how the agreement is revised. Keep it separate from, or severable from, the commercial terms; FDA may review it during an inspection.

Terms Worth Negotiating

These are the terms that decide how the partnership behaves under pressure. There are few published market standards for them, so negotiate from your own risk rather than a template.

• Process improvements: Who owns improvements made at the CDMO. A common split gives the sponsor improvements that rely on its own process knowledge and leaves general manufacturing improvements with the CDMO; the line is not always clear, so define it.
• Batch failure: Usually the most contested term. The CDMO normally pays for failures caused by its own errors; disputes start when the cause is the transferred process, the documents or the materials the sponsor qualified. Liability is commonly capped, for example at the batch cost or a multiple of annual fees, with exceptions for wilful misconduct, gross negligence and third-party claims.
• Forecasts and capacity: How binding your forecasts are, how much capacity is reserved and what happens if you order less. There is no market-standard figure; tie commitments to your development stage and demand data.
• Exit and transfer out: The CDMO’s duty to hand over documents and help transfer the process to another site, and who pays for that transfer, set out before anyone needs it.
• Regulatory status: For any CDMO with China links: representations on BIOSECURE and 1260H status, a duty to notify you of a designation, and termination or substitution rights if one happens.

Second Sourcing and Resilience

A second qualified site is expensive, so decide deliberately where you need one. FDA’s draft guidance on risk management plans, written under the CARES Act, recommends planning for redundancy when a product relies on a single API or finished-dose manufacturer, has no alternative, or comes from a site with an official-action-indicated inspection in the past five years and no other qualified site, and reviewing the plan at least once a year. In Europe, the Critical Medicines Act, provisionally agreed in May 2026 and awaiting a final vote in Parliament, would make security of supply a bigger factor in how medicines are bought.

Two triggers tend to force the decision. The first is a geopolitical designation: after WuXi AppTec was added to the US 1260H list in June 2026, a federal court found that customers and suppliers had cancelled contracts and moved programs within weeks. The second is a change of ownership: when Novo Holdings completed its roughly US$16.5 billion acquisition of Catalent in December 2024, three sites passed to Novo Nordisk. For an approved product, switching takes time; a 2024 BIO survey estimated up to eight years.

BIOSECURE, China and Your CDMO

The BIOSECURE Act was enacted on December 18, 2025 as section 851 of the FY2026 National Defense Authorization Act. It is often described as a ban on Chinese CDMOs; it is narrower than that.

• What it covers: US federal purchases of biotechnology equipment or services from biotechnology companies of concern, federal contractors that use them in performing the contract, and federal grants and loans. It does not ban purely private contracts.
• Who is covered: companies on the Pentagon’s 1260H list and companies designated by the Office of Management and Budget, whose first list is due by December 18, 2026.
• When: the prohibitions apply only after the federal procurement rules are revised, expected by about mid 2028, plus 60 or 90 days, so from around late 2028.
• Existing contracts: generally grandfathered for five years, except contracts with companies that were already on the 1260H list when the law was enacted.

WuXi AppTec was added to the 1260H list on June 8, 2026; a federal court preliminarily blocked the Pentagon from giving that designation effect on August 7, 2026, and the case continues. WuXi Biologics is not on the 1260H list, although the OMB route remains open. Separately, the Pentagon may not contract directly with 1260H-listed companies from June 30, 2026, a rule that reaches its supply chain from June 30, 2027.

For any CDMO with China links, write in representations on its BIOSECURE and 1260H status, a duty to notify you of a designation, termination or substitution rights if one happens, and an agreed split of the cost of moving the process. Our BIOSECURE Act analysis has the full timeline.

A Preparation Checklist

1. Decide what you need the CDMO for: development, clinical supply, commercial supply or a second source, and by when.
2. Assemble the transfer package: process description and map, analytical methods, specifications, stability data, batch history, cell bank documentation and the process development history.
3. Write down the data gaps you already know about. CDMOs price and plan better when they see them early.
4. Build a demand forecast by phase, with ranges rather than false precision.
5. Shortlist on modality experience, inspection history, analytical capability, realistic capacity, project management and financial health, not on GMP status alone.
6. Check inspection records in the FDA Data Dashboard and EudraGMDP before the first visit.
7. Run a qualification audit, with the right to audit subcontractors written into the contract.
8. Plan the tech transfer as a project with a fit/gap analysis, a risk assessment and named experts on both sides.
9. Negotiate the quality agreement separately from the commercial contract.
10. Agree improvements, batch-failure liability, forecasts, exit and regulatory-status terms before the first batch, and decide whether the product needs a second source.

The Bottom Line

The CDMO you choose matters less than how well the partnership is prepared. Start early, send an honest package, audit what matters, plan the technology transfer in quarters, keep the quality agreement separate and settle the hard terms before the first batch, not after the first failure.

Vision Lifesciences is one of the leading cross-border partnership advisors in life sciences, with teams in Hong Kong, Shanghai, Zurich and Chicago. Our strategic partnerships practice helps pharma and biotech companies find manufacturing and development partners and structure alliances that keep working after signing. If you are preparing a CDMO partnership, talk to our team.

This guide summarizes regulatory guidance, published practice and public reporting as of November 6, 2026 for business planning. It is not legal or regulatory advice.